JP2020183374A - リン酸エステルの新規合成法 - Google Patents
リン酸エステルの新規合成法 Download PDFInfo
- Publication number
- JP2020183374A JP2020183374A JP2020066704A JP2020066704A JP2020183374A JP 2020183374 A JP2020183374 A JP 2020183374A JP 2020066704 A JP2020066704 A JP 2020066704A JP 2020066704 A JP2020066704 A JP 2020066704A JP 2020183374 A JP2020183374 A JP 2020183374A
- Authority
- JP
- Japan
- Prior art keywords
- diastereomer
- group
- alcohol
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001308 synthesis method Methods 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 claims abstract description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 19
- ZMQDTYVODWKHNT-UHFFFAOYSA-N tris(2,2,2-trifluoroethyl) phosphate Chemical compound FC(F)(F)COP(=O)(OCC(F)(F)F)OCC(F)(F)F ZMQDTYVODWKHNT-UHFFFAOYSA-N 0.000 claims abstract description 14
- -1 phosphate triester Chemical class 0.000 claims description 74
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 33
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 30
- 238000005809 transesterification reaction Methods 0.000 claims description 30
- 229910019142 PO4 Inorganic materials 0.000 claims description 25
- 239000010452 phosphate Substances 0.000 claims description 24
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 claims description 21
- 125000006239 protecting group Chemical group 0.000 claims description 15
- 150000001298 alcohols Chemical class 0.000 claims description 12
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 11
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 10
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 claims description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 9
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 claims description 9
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- 150000001340 alkali metals Chemical class 0.000 claims description 7
- 150000003138 primary alcohols Chemical class 0.000 claims description 7
- 150000003333 secondary alcohols Chemical class 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 3
- 239000005549 deoxyribonucleoside Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000002342 ribonucleoside Substances 0.000 claims description 3
- 150000003509 tertiary alcohols Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 37
- 239000013076 target substance Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 135
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 123
- 239000011734 sodium Substances 0.000 description 96
- 238000003756 stirring Methods 0.000 description 53
- 239000000203 mixture Substances 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000000047 product Substances 0.000 description 35
- 238000004440 column chromatography Methods 0.000 description 32
- 229910052739 hydrogen Inorganic materials 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 235000021317 phosphate Nutrition 0.000 description 24
- 239000007853 buffer solution Substances 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- 229910017053 inorganic salt Inorganic materials 0.000 description 21
- 238000001914 filtration Methods 0.000 description 20
- ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000012230 colorless oil Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 14
- 229910052698 phosphorus Inorganic materials 0.000 description 14
- 239000011574 phosphorus Substances 0.000 description 14
- 238000001816 cooling Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 150000002314 glycerols Chemical class 0.000 description 9
- 150000003014 phosphoric acid esters Chemical class 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IWYHWZTYVNIDAE-UHFFFAOYSA-N 1h-benzimidazol-1-ium;trifluoromethanesulfonate Chemical compound OS(=O)(=O)C(F)(F)F.C1=CC=C2NC=NC2=C1 IWYHWZTYVNIDAE-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000006130 Horner-Wadsworth-Emmons olefination reaction Methods 0.000 description 2
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- KJBMLEDGPWAQBR-UHFFFAOYSA-N carbonic acid;n-ethylethanamine Chemical compound OC([O-])=O.CC[NH2+]CC KJBMLEDGPWAQBR-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- QDFXRVAOBHEBGJ-UHFFFAOYSA-N 3-(cyclononen-1-yl)-4,5,6,7,8,9-hexahydro-1h-diazonine Chemical compound C1CCCCCCC=C1C1=NNCCCCCC1 QDFXRVAOBHEBGJ-UHFFFAOYSA-N 0.000 description 1
- NZTFBVLUMJZKHT-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene;2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21.C1CCCCCCCCC=C1C1=NNCCCCCCCC1 NZTFBVLUMJZKHT-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- SAGINAGERRNGGV-UHFFFAOYSA-N benzyl n-(2-hydroxyethyl)carbamate Chemical compound OCCNC(=O)OCC1=CC=CC=C1 SAGINAGERRNGGV-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 125000006007 trichloroethoxy group Chemical group 0.000 description 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Landscapes
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
[1]塩基性反応促進剤の存在下、リン酸トリス(2,2,2−トリフルオロエチル)とアルコールとを反応させることを特徴とするリン酸トリエステルの製造方法。
[2]異なるアルコールを順次反応させることを特徴とする[1]記載のリン酸トリエステルの製造方法。
[3]前記塩基性反応促進剤が、ジアザビシクロウンデセン、t-BuOM(Mは、アルカリ金属を表す。)及びn-BuLiから選ばれる少なくとも1種であることを特徴とする[1]又は[2]記載のリン酸トリエステルの製造方法。
[4]前記リン酸トリス(2,2,2−トリフルオロエチル)及びアルコールの一段階目のエステル交換反応における塩基性促進剤が、ジアザビシクロウンデセン又はt-BuOM(Mは、アルカリ金属を表す。)であり、二段階目のエステル交換反応における塩基性促進剤が、t-BuOM(Mは、アルカリ金属を表す。)であり、三段階目のエステル交換反応における塩基性促進剤が、t-BuOLi、又はn-BuLiであることを特徴とする[1]〜[3]のいずれか記載のリン酸トリエステルの製造方法。
[6]前記アルコールの少なくとも1つは、エステル交換後に脱保護が容易なアルコールであることを特徴とする[1]〜[5]のいずれか記載のリン酸トリエステルの製造方法。
[7]前記エステル交換後に脱保護が容易なアルコールが、水酸基又はアミノ基の保護基を具備するアルコールであることを特徴とする[6]記載のリン酸トリエステルの製造方法。
[8]前記アルコールの少なくとも1つは、リボヌクレオシド又はデオキシリボヌクレオシドであることを特徴とする[1]〜[7]のいずれか記載のリン酸トリエステルの製造方法。
本発明の製造方法においては、同一のアルコールを順次反応させてもよいが、異なる2種又は3種のアルコールを順次反応させることが好ましい。本発明の製造方法においては、異なるエステル部を有する種々のリン酸トリエステルを効率的に製造することができる。
塩基性反応促進剤としては、本発明のエステル交換反応を促進させるものであれば特に制限されるものではなく、ジアザビシクロウンデセン(1,8-diazabicyclo[5.4.0]undec-7-ene,DBU)、ジアザビシクロノネン(1,5-diazabicyclo[4.3.0]non-5-ene, DBN)、t-BuOM(Mは、アルカリ金属を表す(以下同様)。)、n-BuM等を挙げることができる。これらの中でも、ジアザビシクロウンデセン、t-BuOM、n-BuLiが好ましい。Mとしては、Li、Na、K等が挙げられ、Li、Naが好ましく、Liが特に好ましい。
本発明の製造方法で用いる溶媒としては、トルエン、テトラヒドロフラン、クロロベンゼン(好ましくはモノクロロベンゼン)、ジオキサン(好ましくは1,4−ジオキサン)、フルオロベンゼン、ジクロロエタン、アセトノニトリル、N,N−ジメチルホルムアミド(DMF)、ジメチルスルホキシド(DMSO)等の有機溶媒を挙げることができ、これらは混合して用いてもよい。
リン酸トリス(2,2,2−トリフルオロエチル)及びアルコールを反応させる温度(反応温度)としては、−100℃〜50℃程度が好ましく、−50℃〜常温(25℃)程度がより好ましく、−50℃〜10℃程度がさらに好ましい。
(1)1級アルコール
(実験項1)
13C NMR (126 MHz, CDCl3) δ 155.68, 122.22 (dq, Jd = 9.3 Hz, Jq = 277.2 Hz), 79.93, 68.61, 64.01 (dq, Jd = 4.5 Hz, Jq = 38.2 Hz), 40.60, 28.26.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -1.56.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.39 (t, J = 7.8 Hz).
IR (ATR) 3340, 2980, 1699, 1522, 1269, 1164, 1075, 1036, 962, 892, 840, 781
MS (ESI) m/z 428 (M+Na)+
HRMS (ESI) calcd for C11H18F6N1Na1O6P1 (M+Na)+ 428.06736, found 428.06767.
13C NMR (126 MHz, CDCl3) δ 156.29, 136.18, 128.54, 128.25, 128.14, 122.20 (dq, Jd = 9.4 Hz, Jq = 277.5 Hz), 68.31 (d, J = 6.0 Hz), 67.00, 64.00 (dq, Jd = 4.5 Hz, Jq = 38.3 Hz), 41.06 (d, J = 6.4 Hz).
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -1.54.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.39 (t, J = 7.8 Hz).
IR (ATR) 3329, 1703, 1531, 1455, 1423, 1265, 1165, 1074, 1045, 961.
MS (ESI) m/z 462 (M+Na)+
HRMS (ESI) calcd for C14H16F6N1Na1O6P1 (M+Na)+ 462.05171, found 462.05248.
(実験項3)
13C NMR (126 MHz, CDCl3) δ 156.19, 132.55, 122.22 (dq, Jd = 9.4 Hz, Jq = 277.8 Hz), 117.92, 68.34 (d, J = 6.2 Hz), 65.83, 64.03 (dq, Jd = 4.4 Hz, Jq = 38.3 Hz), 41.02 (d, J = 6.3 Hz).
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -1.51.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.38 (t, J = 7.8 Hz).
IR (ATR) 3332, 1708, 1534, 1458, 1424, 1266, 1165, 1074, 1045, 962.
MS (ESI) m/z 412 (M+Na)+
HRMS (ESI) calcd for C10H14F6N1Na1O6P1 (M+Na)+ 412.03606, found 412.03644.
上記のように、1級アルコールの場合、塩基性反応促進剤としてDBUを用いると反応は高収率で進行したが、2級アルコールとの交換反応では、下記に示すように、塩基性反応促進剤としてt-BuOLiの方が優れていた。
まず、除去(脱保護)が容易なtBuOHの導入における反応条件を検討した。
13C NMR (126 MHz, CDCl3) δ 155.72, 122.63 (dq, Jd = 10.6 Hz, Jq = 277.6 Hz), 85.30 (d, J = 7.3 Hz), 79.61, 67.21 (d, J = 5.9 Hz), 63.24 (dq, Jd = 4.5 Hz, Jq = 37.6 Hz,), 40.73 (d, J = 6.2 Hz), 29.65 (d, J = 4.2 Hz), 28.28.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -5.6.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.59 (t, J =8.0 Hz).
IR (ATR) 3348, 2984, 1707, 1688, 1535, 1516, 1268, 1247, 1157, 966, 960.
MS (ESI) m/z 402 (M+Na)+
HRMS (ESI) calcd for C13H25F3N1Na1O6P1 (M+Na)+ 402.12693, found 402.12865.
13C NMR (126 MHz, CDCl3) δ 156.24, 136.26, 134.97 (d, J = 6.3 Hz), 129.01, 128.74, 128.50, 128.18, 128.16, 128.09, 122.42 (dq, Jd = 9.4 Hz, Jq = 277.8 Hz), 70.25 (d, J = 6.3 Hz), 66.87, 63.55 (dq, Jd = 4.4 Hz, Jq = 38.0 Hz,), 41.14 (d, J = 6.3 Hz).
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -0.90.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.46 (t, J = 7.8 Hz).
IR (ATR) 3325, 1702, 1535, 1456, 1423, 1264, 1165, 1074, 1043 961.
MS (ESI) m/z 470 (M+Na)+
HRMS (ESI) calcd for C19H21F3N1Na1O6P1 (M+Na)+ 470.09563, found 470.09553.
13C NMR (126 MHz, CDCl3) δ 156.16, 132.63, 131.67 (d, J = 6.3 Hz), 122.47 (dq, Jd = 9.4 Hz, Jq = 277.8 Hz), 119.31, 117.82, 69.06 (d, J = 5.2 Hz), 67.52 (d, J = 6.2 Hz), 65.75, 63.67 (dq, Jd = 4.4 Hz, Jq = 37.8 Hz), 41.16 (d, J = 6.2 Hz).
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -0.82.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.44 (t, J =7.8 Hz).
IR (ATR) 3312, 1716, 1534, 1459, 1425, 1259, 1166, 1019, 989, 963.
MS (ESI) m/z 370 (M+Na)+
HRMS (ESI) calcd for C11H17F3N1Na1O6P1 (M+Na)+ 370.06433, found 370.06464.
まず、下記反応式に示すように、実験項5で得られたリン酸エステル及びフェネチルアルコールを用いて、n-BuLiの反応促進剤としての性能を調査した。
13C NMR (126 MHz, CDCl3) δ 155.79, 83.31 (d, J = 7.0 Hz, the other diastereomer), 83.26 (d, J = 6.8 Hz, one diastereomer), 79.39, 72.02 (d, J = 9.1 Hz), 68.39 (d, J = 6.0 Hz), 66.53, 64.15 (the other diastereomer r), 64.11 (one diastereomer), 40.97 (d, J = 5.0 Hz), 29.80 (d, J = 4.1 Hz), 28.37, 25.87 (the other diastereomer), 25.76 (one diastereomer), 18.27 (the other diastereomer), 18.09 (one diastereomer), -4.69, -4.73, -5.42, -5.46.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -4.7.
IR (ATR) 3317, 2953, 2929, 2857, 1714, 1688, 1521, 1472, 1362, 1251, 1000, 834, 776.
MS (ESI) m/z 622 (M+Na)+
HRMS (ESI) calcd for C26H58N1Na1O8P1Si2 (M+Na)+ 622.33363, found 622.33433.
13C NMR (126 MHz, CDCl3) δ 155.81, 138.13 (the other diastereomer), 138.07 (one diastereomer), 137.98, 128.41, 128.38, 127.84, 127.78, 127.76, 127.71. 127.67, 127.65, 132.75 (one diastereomer), 132.37 (the other diastereomer), 83.64 (d, J = 7.3 Hz, the other diastereomer), 83.55 (d, J = 6.3 Hz, one diastereomer), 79.40, 76.60 (d, J = 6.3 Hz, one diastereomer), 76.54 (d, J = 5.2 Hz, the other diastereomer), 73.48, 72.24, 69.15, 66.64-66.43 (overlapping multiplet; two carbons of each diastereomer), 40.90 (d, J = 5.3 Hz, the other diastereomer), 40.89 (d, J = 4.2 Hz, one diastereomer), 29.79 (d, J = 4.2 Hz), 28.39.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -4.69 (one diastereomer), -4.76 (the other diastereomer).
IR (ATR) 2920, 2852, 1707, 1514, 1455, 1366, 1254, 1170, 1098, 997.
13C NMR (126 MHz, CDCl3) δ 155.85, 134.74 (one diastereomer), 134.71 (the other diastereomer), 134.51, 117.30 (one diastereomer), 117.22 (the other diastereomer), 117.18 (one diastereomer), 117.15 (the other diastereomer), 83.64 (d, J = 6.3 Hz, the other diastereomer), 83.56 (d, J = 7.4 Hz, one diastereomer), 79.42, 76.43 (d, J = 5.2 Hz, one diastereomer), 76.37 (d, J = 4.7 Hz, the other diastereomer), 72.41, 71.30, 69.00 (d, J = 5.2 Hz), 66.66 (d, J = 4.9 Hz), 66.53 (d, J = 6.2 Hz, one diastereomer), 66.48 (d, J = 7.3 Hz), 40.97 (d, J = 5.2 Hz), 29.83 (one diastereomer), 29.79 (the other diastereomer), 28.40.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -4.71 (one diastereomer), -4.75 (the other diastereomer).
IR (ATR) 2978, 2919, 1710, 1519, 1457, 1393, 1252, 1171, 994.
13C NMR (126 MHz, CDCl3) δ 156.26, 136.40, 135.72 (d, J = 6.1 Hz), 128.64 (one diastereomer), 128.62 (the other diastereomer), 128.48, 128.10, 128.07, 127.98, 127.95, 71.93 (d, J = 8.3 Hz), 69.43 (d, J = 5.3 Hz, the other diastereomer), 69.42 (d, J = 5.2 Hz, one diastereomer), 69.07 (d, J = 6.3 Hz, the other diastereomer), 69.03 (d, J = 4.1 Hz, one diastereomer), 66.79, 64.00 (the other diastereomer), 63.98 (one diastereomer), 41.37 (d, J = 6.0 Hz), 25.85, 25.74, 18.26, 18.08, -4.72, -4.78, -5.44, -5.48.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ 0.00.
IR (ATR) 3293, 2951, 2928, 2855, 1719, 1534, 1462, 1423, 1251, 1101, 1009, 883, 776.
MS (ESI) m/z 690 (M+Na)+
HRMS (ESI) calcd for C32H54N1Na1O8P1Si2 (M+Na)+ 690.30233, found 690.30107.
13C NMR (126 MHz, CDCl3) δ 156.25, 136.40, 135.77 (d, J = 6.3 Hz), 128.58, 128.48, 128.08, 128.06, 127.93, 127.87, 72.04 (d, J = 8.3 Hz, one diastereomer), 72.01 (d, J = 8.3 Hz, the other diastereomer), 69.37(d, J = 5.0 Hz, the other diastereomer), 69.33(d, J = 4.7 Hz, one diastereomer), 69.08(d, J = 6.3 Hz, one diastereomer), 69.02 (d, J = 6.3 Hz, the other diastereomer), 66.77 (the other diastereomer), 63.91 (one diastereomer), 41.38 (d, J = 6.0 Hz), 17.97, 17.92, 12.36, 11.84.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ 0.08.
IR (ATR) 2942, 2865, 1723, 1458, 1256, 1011, 881, 773.
MS (ESI) m/z 774 (M+Na)+
HRMS (ESI) calcd for C38H66N1Na1O8P1Si2 (M+Na)+ 774.39623, found 774.39378.
13C NMR (126 MHz, CDCl3) δ 156.16, 132.74, 132.34 (d, J = 6.9 Hz), 118.44, 117.66, 71.92 (d, J = 8.0 Hz), 69.05 (d, J = 6.0 Hz, one diastereomer), 69.03 (d, J = 5.9 Hz, the other diastereomer), 69.27 (d, J = 5.1 Hz), 66.79, 65.64, 63.97 (one diastereomer), 63.92 (the other diastereomer), 41.35 (d, J = 5.7 Hz), 25.84, 25.72, 18.25, 18.07, -4.73, -4.80, -5.46, -5.50.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -0.02.
IR (ATR) 3312, 2951, 2929, 2889, 2856, 1724, 1534, 1463, 1361, 1251, 1101, 1018, 986, 833, 775.
MS (ESI) m/z 590 (M+Na)+
HRMS (ESI) calcd for C24H50N1Na1O8P1Si2 (M+Na)+ 590.27103, found 590.27039.
13C NMR (126 MHz, CDCl3) δ 156.17, 132.75, 132.37 (d, J = 6.9 Hz), 118.35 (d, J = 3.5 Hz), 117.64, 72.06 (d, J = 9.5 Hz, one diastereomer), 72.03 (d, J = 9.5 Hz, the other diastereomer), 69.07 (d, J = 6.3 Hz, one diastereomer), 69.02 (d, J = 6.3 Hz, the other diastereomer), 68.26 (d, J = 5.2 Hz, one diastereomer), 68.24 (d, J = 5.2 Hz, the other diastereomer), 66.76 (d, J = 5.8 Hz), 65.65, 63.90 (one diastereomer), 63.86 (the other diastereomer), 41.38 (d, J = 6.9 Hz), 17.97, 17.92, 12.37, 11.85.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ 0.10.
IR (ATR) 2942, 2866, 1725, 1461, 1256, 1013, 987, 881.
MS (ESI) m/z 674 (M+Na)+
HRMS (ESI) calcd for C30H62N1Na1O8P1Si2 (M+Na)+ 674.36493, found 674.36362.
13C NMR (126 MHz, CDCl3) δ 156.2, 134.1, 134.0, 133.9, 132.8, 119.6, 119.5, 117.6, 88.3, 88.24, 88.19, 88.16, 88.10, 72.03, 72.01, 71.96, 71.82, 71.80, 71.72, 71.70, 70.4-70.2 (m), 69.0-68.7 (m), 66.7-66.5 (m), 65.6, 57.6, 57.4, 41.42 (d, J = 8.2 Hz), 41.36 (d, J = 7.4 Hz), 34.94, 34.88, 31.89, 29.94, 29.90, 29.72, 29.68, 29.63, 29.59, 29.3, 26.83, 26.82, 26.7, 25.9, 25.7, 25.6, 22.7, 18.1, 17.8, 17,7, 14.1, 10.9, 10.8, -4.79, -4.85.
(1)Boc-tBu保護の場合
(実験項17)
13C NMR (126 MHz, CDCl3) δ 138.13, 138.00, 128.30, 127.74, 127.60, 127.56, 76.66, 73.25, 72.06, 69.23, 66.38 (d, J = 5.3 Hz), 62.91 (d, J = 4.6 Hz), 40.16 (d, J = 5.1 Hz).
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -0.53.
IR (ATR) 3011, 2869, 2919, 1608, 1498, 1453, 1215, 1021, 747.
13C NMR (126 MHz, CDCl3) δ 134.77, 134.52, 117.16, 117.02, 76.47 (d, J = 7.5 Hz), 72.23, 71.13, 69.05, 66.33 (d, J = 5.2 Hz), 62.97, 40.32 (d, J = 4.5 Hz).
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -0.54.
IR (ATR) 3422, 2869, 1624, 1520, 1457, 1425, 1219, 1015, 920, 751.
(実験項19)
13C NMR (126 MHz, CDCl3) δ 72.64 (d, J = 9.3 Hz), 67.09 (d, J = 5.0 Hz), 64.78, 61.96 (d, J = 3.1 Hz), 40.50, 25.96, 25.86, 18.31, 18.15, -4.59, -4.61, -5.29, -5.32.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ 1.17.
13C NMR (126 MHz, CDCl3) δ 72.78 (d, J = 9.4 Hz), 67.20 (d, J = 5.3 Hz), 64.71, 61.88 (d, J = 3.1 Hz), 40.52, 18.07, 17.99, 12.45, 11.96.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ 1.55.
IR (ATR) 2941, 2865, 1636, 1542, 1460, 1383, 1225, 1069, 1031, 881.
MS (ESI) m/z 550 (M+Na)+
HRMS (ESI) calcd for C23H54N1Na1O6P1Si2 (M+Na)+ 550.31250, found 550.31054.
(実験項21)
(実験項23)
その後、TBS脱保護体とオクタデカン酸454 mg (1.6 mmol)、ジメチルアミノピリジン77 mg (0.63 mmol)、ジクロロメタン6 mlを加えた。0 ℃に冷却後、1-(3-ジメチルアミノプロピル)-3-エチルカルボジイミド363 mg (1.9 mmol)を加えた。室温にて12時間撹拌後、反応液を濃縮し、得られる残分をカラムクロマトグラフィー(ヘキサン/酢酸エチル= 3 / 2)にて精製することで目的物をジアステレオマー混合物(リン上の不斉点とグリセロール上の不斉点とに由来)として得た。収量 430 mg (0.48 mmol) (収率 70 % (2steps))、無色液体(Colorless oil)であった。
13C NMR (126 MHz, CDCl3) δ 173.24, 172.84 (the other diastereomer), 172.83 (one diastereomer), 155.77, 84.05 (d, J = 7.5 Hz, the other diastereomer), 83.98 (d, J = 8.3 Hz, one diastereomer), 79.47, 69.40 (d, J = 8.3 Hz), 66.79 (d, J = 6.1 Hz), 64.91 (d, J = 5.2 Hz), 61.76, 40.89 (d, J = 7.1 Hz), 34.15, 34.01, 31.90, 31.56, 29.76, 29.73, 29.68, 29.64, 29.62, 29.47, 29.34, 29.27, 29.11, 29.08, 28.34, 24.82, 22.67, 22.62, 14.09.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -4.79 (the other diastereomer), -4.86 (one diastereomer).
IR (ATR) 2915, 2849, 1741, 1714, 1523, 1466, 1366, 1253, 1168, 1039, 996.
MS (ESI) m/z 927 (M+Na)+
HRMS (ESI) calcd for C50H98N1Na1O10P1 (M+Na)+ 926.68260, found 926.68169.
13C NMR (126 MHz, CDCl3) δ 173.25, 172.92, 69.65 (d, J = 7.8 Hz), 64.81 (d, J = 5.6 Hz), 63.02 (d, J = 3.6 Hz), 62.08, 40.30, 34.20, 34.03, 29.73, 29.67, 29.59, 29.58. 29.40, 29.37, 29.21, 29.16, 24.90, 24.86, 22.68, 14.10.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -0.54.
IR (ATR) 2915, 2849, 1735, 1466, 1170, 1064, 1019, 820.
MS (ESI) m/z 747 (M-2H-Cl)-
(実験項25)
<化合物(13)の製造>
13C NMR (126 MHz, CDCl3) δ 170.1, 155.6, 139.3, 132.1, 122.2 (dq, Jd = 9.2 Hz, Jq = 277.6 Hz), 118.1, 104.9, 86.6, 84.5 (d, J = 7.4 Hz), 70.5, 67.7, 67.6 (d, J = 6.2 Hz), 64.1 (dq, Jd = 4.0 Hz, Jq = 38.6 Hz), 41.3, 25.6, 17.9, 12.0, -4.7, -5.1
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.1.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.48-86.43 (m).
IR (ATR) 2953, 2933, 2858, 1666, 1533, 1470, 1417, 1270, 1168, 1075 cm-1
MS (ESI) m/z 663 (M+Na)+
HRMS (ESI) calcd for C23H35F6N2Na1O8P1Si1 (M+Na)+ 663.17022, found 663.17099
13C NMR (126 MHz, CDCl3) δ 170.07, 170.05, 170.01, 158.77, 158.76, 155.64, 155.63, 155.5, 144.00, 143.98, 139.4, 139.3, 139.2, 135.00, 134.98, 132.13, 132.10, 132.0, 130.0, 128.02, 127.97, 127.21, 127.19, 122.3 (q, J = 278.3 Hz), 118.2, 118.1, 113.3, 105.2, 105.1, 104.9, 104.8, 87.2, 86.6, 86.4, 86.0, 85.8, 84.7-84.4 (m), 79.52 (d, J = 5.1 Hz), 79.48 (d, J = 4.4 Hz), 70.7, 70.5, 67.7 (d, J = 8.3 Hz), 67.4 (d, J = 6.2 Hz), 67.2 (d, J = 6.2 Hz), 64.3-63.3 (m), 62.9 (d, J = 3.1 Hz), 55.2, 41.3 (d, J = 1.9 Hz), 40.0 (d, J = 4.2 Hz), 39.9 (d, J = 4.1 Hz), 25.6, 17.8, 12.0, 11.60, 11.56, -4.70, -4.73, -5.0.
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.5 (one diastereomer), -1.6 (the other diastereomer).
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.68 (dd, J = 7.8, 7.8 Hz, one diastereomer), 86.59 (dd, J = 8.2, 8.2 Hz, the other diastereomer).
IR (ATR) 2930, 2855, 1665, 1607, 1530, 1508, 1465, 1404, 1322, 1173, 1101, 829, 700 cm-1
MS (ESI) m/z 1147 (M+Na)+
HRMS (ESI) calcd for C55H68F3N4Na1O14P1Si1 (M+Na)+ 1147.40887, found 1147.41202.
13C NMR (126 MHz, CDCl3) δ 170.1, 170.03, 169.98, 158.8, 155.71, 155.65, 155.63, 144.1, 139.41, 139.36, 139.33, 136.52, 136.46, 135.2, 135.12, 135.11, 135.07, 132.21, 132.19, 132.10, 130.1, 128.9, 128.60, 128.58, 128.1, 128.0, 127.2, 126.9, 118.2, 118.1, 113.3, 105.14, 105.05, 104.8, 104.7, 87.1, 86.4, 86.2, 85.9, 85.8, 84.9-84.7 (m), 78.8 (d, J = 5.5 Hz), 78.6 (d, J = 5.3 Hz), 70.8, 70.7, 68.59 (d, J = 6.0 Hz), 68.57 (d, J = 6.6 Hz), 67.75, 67.67, 66.43, 66.40, 63.2, 63.1, 55.2, 41.53, 41.49, 40.0 (d, J = 4.4 Hz), 25.69, 25.67, 17.9, 12.1, 11.6, -4.6, -4.7, -4.99, -4.91.
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.2 (one diastereomer), -1.3 (the other diastereomer).
IR (ATR) 3059, 2928, 2854, 1655, 1533, 1465, 1402, 1322, 1249, 1176, 999, 828, 699 cm-1
MS (ESI) m/z 1169 (M+Na)+
HRMS (ESI) calcd for C61H75N4Na1O14P1Si1 (M+Na)+ 1169.46843, found 1169.46992.
13C NMR (126 MHz, CDCl3) δ 170.2, 170.1, 170.0, 169.9, 158.8, 158.7, 155.9, 155.8, 155.7, 155.6, 144.1, 144.0, 139.5, 139.35, 139.28, 139.24, 136.54, 136.50, 135.13, 135.07, 135.04, 132.2, 132.1, 132.0, 131.9, 130.06, 130.04, 130.00, 128.9, 128.6, 128.5, 128.1, 128.02, 128.00, 127.2, 126.9, 126.8, 118.3, 118.2, 118.13, 118.08, 113.3, 105.6, 105.3, 104.9, 104.5, 87.2, 87.1, 86.17, 86.15, 86.0, 85.9, 84.8 (d, J = 8.0 Hz), 84.6 (d, J = 6.3 Hz), 84.4 (d, J = 6.5 Hz), 84.1 (d, J = 7.4 Hz), 79.6 (d, J = 5.1 Hz), 78.8 (d, J = 6.3 Hz), 70.2, 69.3, 68.7 (d, J = 5.4 Hz), 68.5 (d, J = 5.2 Hz), 67.9, 67.8, 67.7, 67.6, 66.8 (d, J = 5.7 Hz), 66.2 (d, J = 5.6 Hz), 63.3, 63.0, 55.2, 41.1, 41.0, 40.1, 39.8, 36.6 (d, J = 7.2 Hz), 36.5 (d, J = 7.3 Hz), 12.15, 12.11, 11.6.
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.0 (one diastereomer), -1.6 (the other diastereomer).
IR (ATR) 3335, 2930, 1661, 1530, 1465, 1403, 1321, 1248, 1175, 1114, 997, 826, 780, 699 cm-1
MS (ESI) m/z 1055 (M+Na)+
HRMS (ESI) calcd for C55H61N4Na1O14P1 (M+Na)+ 1055.38196, found 1055.38383.
13C NMR (126 MHz, CDCl3) δ 164.0, 163.9, 163.81, 163.80, 158.8, 151.0, 150.9, 150.5, 144.1, 144.0, 136.6, 136.5, 135.7, 135.5, 135.1, 135.03, 135.00, 134.96, 130.1, 128.9, 128.60, 128.57, 128.1, 128.0, 127.3, 126.9, 113.3, 112.0, 111.8, 111.3, 111.1, 87.3, 87.2, 85.3, 85.2, 84.6-84.3 (m), 79.6 (d, J = 4.8 Hz), 79.2 (d, J = 5.3 Hz), 71.0, 70.9, 68.70 (d, J = 5.9 Hz), 68.68 (d, J = 5.3 Hz), 67.3 (d, J = 6.3 Hz), 67.0 (d, J = 5.4 Hz), 63.4, 63.3, 40.6, 39.9, 39.1, 38.7, 36.6 (d, J = 7.2 Hz), 36.5 (d, J = 6.2 Hz), 12.4, 11.7.
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.3 (the other diastereomer), -2.0 (one diastereomer).
IR (ATR) 3167, 2959, 2831, 1677, 1605, 1507, 1366, 1248, 1175, 999, 825, 699 cm-1
MS (ESI) m/z 975 (M+Na)+
HRMS (ESI) calcd for C49H53N4Na1O14P1 (M+Na)+ 975.31936, found 975.32148.
<化合物(14)の製造>
13C NMR (126 MHz, CDCl3) δ 171.0, 155.5, 142.1, 131.9, 122.1 (dq, Jd = 9.3 Hz, Jq = 278.3 Hz), 118.7, 95.8, 86.9, 84.6 (d, J = 7.3 Hz), 70.4, 67.7, 67.4 (d, J = 6.7 Hz), 64.1 (dq, Jd = 4.3 Hz, Jq = 38.5 Hz), 41.4, 25.6, 17.9, -4.8, -5.2.
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.1.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.47 (t, J = 7.9 Hz).
IR (ATR) 2951, 2858, 1663, 1628, 1545, 1451, 1399, 1302, 1274, 1163 cm-1
MS (ESI) m/z 649 (M+Na)+
HRMS (ESI) calcd for C22H33F6N2Na1O8P1Si1 (M+Na)+ 649.15457, found 649.15427.
13C NMR (126 MHz, CDCl3) δ 171.05, 171.00, 155.54, 155.50, 155.45, 143.9, 142.35, 142.31, 142.28, 142.19, 134.9, 134.8, 131.94, 131.91, 131.85, 130.0, 128.0, 127. 2, 122.3 (q, J = 268.2 Hz),118.8, 118.7, 113.3, 95.82, 95.78, 95.74, 87.22, 87.20, 86.9, 86.7, 86.5, 86.3, 84.8-84.5 (m), 79.0 (d, J = 5.2 Hz), 78.8 (d, J = 4.4 Hz), 70.7, 70.5, 67.7 (d, J = 7.1 Hz), 67.4 (d, J = 6.2 Hz), 67.1 (d, J = 5.2 Hz), 64.3-63.4 (m), 62.6, 62.5, 55.2, 41.41, 41.38, 40.2, 40.0 (d, J = 4.3 Hz), 31.5, 25.6, 22.6, 14.1, -4.69, -4.72, -5.0, -5.1.
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.5.
19F NMR (470 MHz, CDCl3, Internal standard: Hexafluorobenzene) δ 86.70 (dd, J = 8.1, 8.1 Hz, one diastereomer), 86.65 (dd, J = 7.9, 7.9 Hz, the other diastereomer).
IR (ATR) 2932, 2856, 1663, 1628, 1540, 1508, 1469, 1399, 1249, 1173, 1022, 829, 701cm-1
MS (ESI) m/z 1119 (M+Na)+
HRMS (ESI) calcd for C53H64F3N4Na1O14P1Si1 (M+Na)+ 1119.37757, found 1119.38020.
13C NMR (126 MHz, CDCl3) δ 171.01, 170.99, 170.96, 158.7, 155.6, 155.53, 155.50, 144.0,142.5, 142.4, 142.3, 142.2, 136.53, 136.45, 135.1, 135.0, 134.9, 131.99, 131.89, 130.03, 130.01, 128.90, 128.87, 128.62, 128.59, 128.04, 127.98, 127.2, 126.9, 118.8, 118.64, 118.62, 113.3, 95.7, 87.13, 87.10, 86.7, 86.6, 86.4, 86.3, 84.9 (d, J = 7.6 Hz), 84.8 (d, J = 6.2 Hz), 78.0 (d, J = 4.9 Hz), 70.8, 70.7, 68.65 (d, J = 5.4 Hz), 68.61 (d, J = 6.0 Hz), 67.73, 67.66, 66.5, 66.4, 62.69, 62.65, 55.2, 41.6, 41.5, 40.2 (d, J = 3.5 Hz), 36.58 (d, J = 6.8 Hz), 36.56, (d, J = 7.0 Hz), 25.7, 17.9, -4.6, -4.7, -4.92, -4.94.
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.1 (one diastereomer), -1.2 (the other diastereomer).
IR (ATR) 3059, 2928, 2855, 1664, 1627, 1540, 1508, 1468, 1397, 1248, 1175, 999, 780 cm-1
MS (ESI) m/z 1141 (M+Na)+
HRMS (ESI) calcd for C59H71N4Na1O14P1Si1 (M+Na)+ 1141.43713, found 1141.43633.
13C NMR (126 MHz, CDCl3) δ 171.2, 171.1, 171.00, 170.95, 158.7, 155.8, 155.64, 155.58, 155.54, 144.02, 143.97, 142.4, 142.30, 142.28, 142.16, 136.6, 136.5, 135.0, 134.9, 132.0, 131.9, 131.8, 131.7, 130.1, 130.0, 128.9, 128.62, 128.61, 128.02, 128.00, 127.2, 126.9, 118.9, 118.8, 118.7, 118.6, 113.3, 96.1, 95.84, 95.76, 95.5, 87.14, 87.13, 86.62, 86.56, 86.44, 86.39, 84.8 (d, J = 7.3 Hz), 84.7 (d, J = 6.3 Hz), 84.5 (d, J = 6.1 Hz), 84.3 (d, J = 7.3 Hz), 79.0 (d, J = 4.5 Hz), 78.1 (d, J = 5.6 Hz), 70.3, 69.5, 68.7 (d, J = 5.7 Hz), 68.6 (d, J = 6.2 Hz), 67.9, 67.8, 67.70, 67.66, 66.7 (d, J = 6.4 Hz), 66.3 (d, J = 5.2 Hz), 62.9, 62.6, 41.1, 41.0, 40.2, 40.1, 36.6 (d, J = 7.2 Hz), 36.5 (d, J = 6.9 Hz).
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.1 (the other diastereomer), -1.4 (one diastereomer).
IR (ATR) 3334, 2936, 16511, 1627, 1540, 1469, 1397, 1301, 1248, 1175, 1114, 998, 827, 699 cm-1
MS (ESI) m/z 1027 (M+Na)+
HRMS (ESI) calcd for C53H57N4Na1O14P1 (M+Na)+ 1027.35066, found 1027.35092.
13C NMR (126 MHz, CDCl3) δ 163.6, 163.5, 163.38, 163.35, 158.7, 150.9, 150.7, 150.5, 144.0, 143.9, 140.0, 139.85, 139.76, 139.5, 136.6, 136.5, 134.9, 134.8, 130.1, 130.0, 128.93, 128.91, 128.6, 128.0, 127.2, 126.9, 113.3, 102.8, 102.75, 102.66, 102.5, 87.3, 85.7, 85.5, 84.81, 84.76, 84.6-84.5 (m), 78.8 (d, J = 4.3 Hz), 70.83, 70.76, 68.75 (d, J = 5.8 Hz), 67.0 (d, J = 4.9 Hz), 63.0, 55.2, 40.1, 40.0, 39.3, 36.53 (d, J = 6.6 Hz), 36.48 (d, J = 5.5 Hz).
31P NMR (202 MHz, CDCl3, External standard: 85% H3PO4) δ -1.3 (the other diastereomer), -1.9 (one diastereomer).
IR (ATR) 3053, 1675, 1507, 1458, 1379, 1246, 1175, 999, 825, 749, 699 cm-1
MS (ESI) m/z 947 (M+Na)+
HRMS (ESI) calcd for C47H49N4Na1O14P1 (M+Na)+ 947.28806, found 947.28974.
Claims (11)
- 塩基性反応促進剤の存在下、リン酸トリス(2,2,2−トリフルオロエチル)とアルコールとを反応させることを特徴とするリン酸トリエステルの製造方法。
- 異なるアルコールを順次反応させることを特徴とする請求項1記載のリン酸トリエステルの製造方法。
- 前記塩基性反応促進剤が、ジアザビシクロウンデセン、t-BuOM(Mは、アルカリ金属を表す。)及びn-BuLiから選ばれる少なくとも1種であることを特徴とする請求項1又は2記載のリン酸トリエステルの製造方法。
- 前記リン酸トリス(2,2,2−トリフルオロエチル)及びアルコールの一段階目のエステル交換反応における塩基性促進剤が、ジアザビシクロウンデセン又はt-BuOM(Mは、アルカリ金属を表す。)であり、
二段階目のエステル交換反応における塩基性促進剤が、t-BuOM(Mは、アルカリ金属を表す。)であり、
三段階目のエステル交換反応における塩基性促進剤が、t-BuOLi、又はn-BuLiである
ことを特徴とする請求項1〜3のいずれか記載のリン酸トリエステルの製造方法。 - 前記アルコールは、1級アルコール、2級アルコール及び3級アルコールから選ばれる少なくとも1種のアルコールであることを特徴とする請求項1〜4のいずれか記載のリン酸トリエステルの製造方法。
- 前記アルコールの少なくとも1つは、エステル交換後に脱保護が容易なアルコールであることを特徴とする請求項1〜5のいずれか記載のリン酸トリエステルの製造方法。
- 前記エステル交換後に脱保護が容易なアルコールが、水酸基又はアミノ基の保護基を具備するアルコールであることを特徴とする請求項6記載のリン酸トリエステルの製造方法。
- 前記アルコールの少なくとも1つが、リボヌクレオシド又はデオキシリボヌクレオシドであることを特徴とする請求項1〜7のいずれか記載のリン酸トリエステルの製造方法。
- 二段階目のエステル交換反応で製造されるリン酸ジエステルが、以下のいずれかの化合物であることを特徴とする請求項1〜8のいずれか記載のリン酸トリエステルの製造方法。
- 請求項1〜9のいずれか記載の方法により製造されたリン酸トリエステルを原料として用いることを特徴とするリン脂質又はオリゴ/ポリヌクレオチドの製造方法。
- 以下のいずれかの化合物からなることを特徴とするリン酸トリエステルを製造するための基質化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019085221 | 2019-04-26 | ||
JP2019085221 | 2019-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020183374A true JP2020183374A (ja) | 2020-11-12 |
Family
ID=73044172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020066704A Pending JP2020183374A (ja) | 2019-04-26 | 2020-04-02 | リン酸エステルの新規合成法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2020183374A (ja) |
-
2020
- 2020-04-02 JP JP2020066704A patent/JP2020183374A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7390417B2 (ja) | 不斉補助基 | |
US10730904B2 (en) | Method for liquid-phase synthesis of nucleic acid | |
JP7279991B2 (ja) | ホスフェート誘導体の合成 | |
US20120178710A1 (en) | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof | |
EP3684780B1 (en) | Floxuridine synthesis | |
JP2020183374A (ja) | リン酸エステルの新規合成法 | |
JP2019513718A (ja) | 2’−フルオロ−6’−メチレン−炭素環アデノシン(fmca)及び2’−フルオロ−6’−メチレン−炭素環グアノシン(fmcg)の合成 | |
JP7433684B1 (ja) | 疑似固相保護基、それを用いたヌクレオシド保護体又はオリゴヌクレオチド保護体、オリゴアミダイト前駆体の製造方法 | |
JP7075681B2 (ja) | 立体制御オリゴヌクレオチド合成用光学活性セグメントおよびその製造方法、ならびにそれを用いた立体制御オリゴヌクレオチドの合成方法 | |
US20030078414A1 (en) | Oligonucleotides having alkylphosphonate linkages and methods for their preparation | |
EP4308580A1 (en) | Chiral synthons for the synthesis of chiral phosphorothioates | |
CN114644651A (zh) | 芳氧基磷酰化氨基酸酯化合物的制备方法 | |
CZ20011145A3 (cs) | Antivirové purinové deriváty a jejich použití |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230202 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240527 |